gpawelski Posted February 24, 2009 Share Posted February 24, 2009 A California based cancer physician is offering a new test that could tell which cancer drugs will be most effective on an individual patient’s cancer. This approach could lead to improved treatment of mesothelioma in the future. Dr. Larry Weisenthal's new series of tests, called Functional Tumor Cell Profiling (FTCP), is a process that takes live cancer cells from a patient and exposes them to a series of anti-cancer drugs to see which will work and which won’t. FTCP could save patients and doctors time and money, while avoiding painful and ineffective treatments. FTCP incubates cancer cells (a gram being the recommended amount) over a 96 hour period. During this time, the sample is exposed to more than twenty different anti-cancer drugs, and in some cases, combinations of drugs. After each drug is used on the sample in multiple doses (to ensure accuracy), three different methods are used to measure the effectiveness of the drug. The results are then compared to the Weisenthal Cancer Group index database. Using this information, Dr. Weisenthal rules out which cancer treatments won’t work, and recommends which show promise. Weisenthal, evaluates all the samples himself, spending 6-8 hours on each one. For Dr. Weisenthal and his team to use FTCP, they must receive a live cancer specimen, preferably a solid mass, although malignant effusions are often useable as well. The cost of the procedure is around $5000. Medicare covers the process, as do most insurers. Source: Mesothelioma Aid Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.